Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight Follows OvaScience’s Unique Route To Going Public

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financial activity by Stem Cells Inc., Sanofi, Avalon Ventures and Aerpio Therapeutics.

You may also be interested in...

OvaScience’s AUGMENT Takes A Pregnant Pause In U.S.

The biotech voluntarily suspended a U.S. trial of its IVF-enhancing cell therapy after receiving word from FDA that it needs to follow a different regulatory path.

RQx Antibiotic Collaboration With Genentech Marks Third Exit For Avalon Ventures This Year

Avalon-backed RQx will team with Genentech to discover and develop antibiotics against a novel, undisclosed target. The deal essentially is an exit for hybrid VC firm Avalon, which already has exit deals this year with BioMarin and Genentech.

Financings Of The Fortnight Considers The Value Of Insider Participation In Biotech IPOs

Plus news on recent financings by Radius Health, Cempra, Ironwood and Acetylon.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts